-DOCSTART- -X- O
Abstract -X- _ O
Many -X- _ O
natural -X- _ B-Intervention
lectins -X- _ I-Intervention
have -X- _ O
been -X- _ O
reported -X- _ O
to -X- _ O
have -X- _ O
antiviral -X- _ O
activity. -X- _ O
As -X- _ O
some -X- _ O
of -X- _ O
these -X- _ O
have -X- _ O
been -X- _ O
put -X- _ O
forward -X- _ O
as -X- _ O
potential -X- _ O
development -X- _ O
candidates -X- _ O
for -X- _ O
preventing -X- _ O
or -X- _ O
treating -X- _ O
viral -X- _ O
infections -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
set -X- _ O
out -X- _ O
in -X- _ O
this -X- _ O
review -X- _ O
to -X- _ O
survey -X- _ O
the -X- _ O
literature -X- _ O
on -X- _ O
antiviral -X- _ O
lectins. -X- _ B-Intervention
The -X- _ O
review -X- _ O
groups -X- _ O
lectins -X- _ O
by -X- _ O
structural -X- _ O
class -X- _ O
and -X- _ O
class -X- _ O
of -X- _ O
source -X- _ O
organism -X- _ O
we -X- _ O
also -X- _ O
detail -X- _ O
their -X- _ O
carbohydrate -X- _ O
specificity -X- _ O
and -X- _ O
their -X- _ O
reported -X- _ O
antiviral -X- _ O
activities. -X- _ O
The -X- _ O
review -X- _ O
concludes -X- _ O
with -X- _ O
a -X- _ O
brief -X- _ O
discussion -X- _ O
of -X- _ O
several -X- _ O
of -X- _ O
the -X- _ O
pertinent -X- _ O
hurdles -X- _ O
that -X- _ O
heterologous -X- _ B-Intervention
proteins -X- _ I-Intervention
must -X- _ O
clear -X- _ O
to -X- _ O
be -X- _ O
useful -X- _ O
clinical -X- _ O
candidates -X- _ O
and -X- _ O
cites -X- _ O
examples -X- _ O
where -X- _ O
such -X- _ O
studies -X- _ O
have -X- _ O
been -X- _ O
reported -X- _ B-Outcome
for -X- _ I-Outcome
antiviral -X- _ I-Outcome
lectins. -X- _ I-Outcome
Though -X- _ O
the -X- _ O
clearest -X- _ O
path -X- _ O
currently -X- _ O
being -X- _ O
followed -X- _ O
is -X- _ O
the -X- _ O
use -X- _ B-Outcome
of -X- _ I-Outcome
antiviral -X- _ I-Outcome
lectins -X- _ I-Outcome
as -X- _ I-Outcome
anti-HIV -X- _ I-Outcome
microbicides -X- _ I-Outcome
via -X- _ I-Outcome
topical -X- _ I-Outcome
mucosal -X- _ I-Outcome
administration -X- _ I-Outcome
, -X- _ O
some -X- _ O
investigators -X- _ O
have -X- _ O
also -X- _ O
found -X- _ O
systemic -X- _ O
efficacy -X- _ O
against -X- _ O
acute -X- _ O
infections -X- _ O
following -X- _ O
subcutaneous -X- _ O
administration -X- _ O
. -X- _ O

